Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
— · Esophageal Cancer, Gastrointestinal Cancers, Gynecologic Cancers · Recruiting · est. 2027-12
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Waters is lead sponsor; 1 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-08-21Current report (material event)
- 10-Q2026-08-11Quarterly report
- 8-K2026-08-04Current report (material event)
- 11-K2026-06-2511-K
- SD2026-05-29SD
- 8-K2026-05-22Current report (material event)
- SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
- 10-Q2026-05-12Quarterly report
- 8-K2026-05-05Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- SCHEDULE 13G/A2026-04-24SCHEDULE 13G/A
- ARS2026-04-09Annual report to holders
- DEFA14A2026-04-09DEFA14A
- DEF 14A2026-04-09Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 8-K2026-03-23Current report (material event)
- 424B22026-03-19424B2
- FWP2026-03-17FWP
- 424B22026-03-16424B2
- S-3ASR2026-03-16S-3ASR
- 8-K2026-03-16Current report (material event)
- S-82026-02-23Employee stock plan
- 10-K2026-02-23Annual report
- 8-K2026-02-09Current report (material event)
- 8-K2026-02-09Current report (material event)
- 8-K2026-01-27Current report (material event)
- 4252026-01-16425
- 8-K2026-01-16Current report (material event)
- 4252026-01-13425
- 4252026-01-12425
- 8-K2026-01-12Current report (material event)
- 4252026-01-12425
- 4252026-01-05425
- EFFECT2025-12-23EFFECT
- 424B32025-12-23424B3
- S-4/A2025-12-19S-4/A
- 4252025-12-15425
- S-42025-12-12S-4
- 4252025-11-18425
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.